Cipla To Pour $460 Million Into Production Expansion In India
This article was originally published in PharmAsia News
India's Cipla says it plans to invest nearly $460 million during the next two years as part of its expansion policy to produce more drugs for domestic and foreign consumption. The funds are to be added to a program already building new facilities and expanding others to take advantage of an anticipated 12 percent to 15 percent growth next year. Part of that growth is expected to be generated by a 10 percent growth in company exports, already comprising half of its business. (Click here for more
You may also be interested in...
Amgen has an open road for its Mvasi bevacizumab biosimilar after Genentech’s appeal to enjoin sales, over a notice of commercial marketing technicality, was denied. The US firm continues to weigh up patent-infringement proceedings in separate actions.
Coronavirus-induced stockpiling and advanced prescribing of medicines has resulted in generics companies across the world registering unprecedented growth during the first quarter of 2020. However, many companies predict sales will level off again in the next quarter and beyond. And as demand fluctuates following the COVID-19 outbreak, companies have started taking precautionary measures to avoid supply-chain disruptions.
Coronavirus Update: Regeneron Races Into Phase III Trial Of Antibodies To Block Coronavirus Infection
Regeneron and NIAID kick off a Phase III prevention trial for antibody cocktail REGN-COV2.